Latest News

Analyst Says Alnylam’s New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for the treatment of transthyretin-mediated (ATTR) 

Latest Ratings for ALNY

DateFirmActionFromTo Mar 2022CitigroupInitiates Coverage OnBuy Feb 2022Morgan StanleyMaintainsOverweight Feb 2022SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for ALNY

View the Latest Analyst Ratings

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News